BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 37107675)

  • 1. Interaction between
    Chen XR; Shao Y; Sadowski MJ; On Behalf Of The Alzheimer's Disease Neuroimaging Initiative
    Genes (Basel); 2023 Apr; 14(4):. PubMed ID: 37107675
    [No Abstract]   [Full Text] [Related]  

  • 2. Klotho allele status is not associated with Aβ and APOE ε4-related cognitive decline in preclinical Alzheimer's disease.
    Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Ames D; Masters CL; Martins RN; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM
    Neurobiol Aging; 2019 Apr; 76():162-165. PubMed ID: 30716541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low testosterone levels relate to poorer cognitive function in women in an APOE-ε4-dependant manner.
    Dratva MA; Banks SJ; Panizzon MS; Galasko D; Sundermann EE;
    Biol Sex Differ; 2024 Jun; 15(1):45. PubMed ID: 38835072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of
    Qian J; Betensky RA; Hyman BT; Serrano-Pozo A
    Neurology; 2021 May; 96(19):e2414-e2428. PubMed ID: 33771840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Klotho-VS Heterozygosity With Risk of Alzheimer Disease in Individuals Who Carry APOE4.
    Belloy ME; Napolioni V; Han SS; Le Guen Y; Greicius MD;
    JAMA Neurol; 2020 Jul; 77(7):849-862. PubMed ID: 32282020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KL∗VS heterozygosity reduces brain amyloid in asymptomatic at-risk APOE∗4 carriers.
    Belloy ME; Eger SJ; Le Guen Y; Napolioni V; Deters KD; Yang HS; Scelsi MA; Porter T; James SN; Wong A; Schott JM; Sperling RA; Laws SM; Mormino EC; He Z; Han SS; Altmann A; Greicius MD; ; ; ;
    Neurobiol Aging; 2021 May; 101():123-129. PubMed ID: 33610961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. APOE ε4 carrier status and sex differentiate rates of cognitive decline in early- and late-onset Alzheimer's disease.
    Polsinelli AJ; Logan PE; Lane KA; Manchella MK; Nemes S; Sanjay AB; Gao S; Apostolova LG
    Alzheimers Dement; 2023 May; 19(5):1983-1993. PubMed ID: 36394443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of apolipoprotein E ε4 allele on the progression of cognitive decline in the early stage of Alzheimer's disease.
    Suzuki K; Hirakawa A; Ihara R; Iwata A; Ishii K; Ikeuchi T; Sun CK; Donohue M; Iwatsubo T;
    Alzheimers Dement (N Y); 2020; 6(1):e12007. PubMed ID: 32211510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of APOE genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's disease.
    Kennedy RE; Cutter GR; Schneider LS
    Alzheimers Dement; 2014 May; 10(3):349-59. PubMed ID: 23712001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Most rapid cognitive decline in APOE epsilon4 negative Alzheimer's disease with early onset.
    van der Vlies AE; Koedam EL; Pijnenburg YA; Twisk JW; Scheltens P; van der Flier WM
    Psychol Med; 2009 Nov; 39(11):1907-11. PubMed ID: 19335933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictability of polygenic risk score for progression to dementia and its interaction with APOE ε4 in mild cognitive impairment.
    Pyun JM; Park YH; Lee KJ; Kim S; Saykin AJ; Nho K;
    Transl Neurodegener; 2021 Aug; 10(1):32. PubMed ID: 34465370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Segmented Linear Mixed Model Analysis Reveals Association of the APOEɛ4 Allele with Faster Rate of Alzheimer's Disease Dementia Progression.
    Chen XR; Shao Y; Sadowski MJ;
    J Alzheimers Dis; 2021; 82(3):921-937. PubMed ID: 34120907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. APOE ε4, Alzheimer's disease neuropathology and sleep disturbance, in individuals with and without dementia.
    Blackman J; Love S; Sinclair L; Cain R; Coulthard E
    Alzheimers Res Ther; 2022 Mar; 14(1):47. PubMed ID: 35354468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KL-VS heterozygosity is associated with lower amyloid-dependent tau accumulation and memory impairment in Alzheimer's disease.
    Neitzel J; Franzmeier N; Rubinski A; Dichgans M; Brendel M; ; Malik R; Ewers M
    Nat Commun; 2021 Jun; 12(1):3825. PubMed ID: 34158479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons.
    Knopman DS; Jack CR; Wiste HJ; Lundt ES; Weigand SD; Vemuri P; Lowe VJ; Kantarci K; Gunter JL; Senjem ML; Mielke MM; Roberts RO; Boeve BF; Petersen RC
    Neurobiol Aging; 2014 Sep; 35(9):2096-106. PubMed ID: 24702820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between white matter hyperintensity severity and cognitive impairment according to the presence of the apolipoprotein E (APOE) ε4 allele in the elderly: retrospective analysis of data from the CREDOS study.
    Son SJ; Lee KS; Lee Y; Baek JH; Choi SH; Na DL; Seo SW; Oh BH; Hong CH
    J Clin Psychiatry; 2012 Dec; 73(12):1555-62. PubMed ID: 23146133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial levels of β-amyloid and tau deposition have distinct effects on longitudinal tau accumulation in Alzheimer's disease.
    Cai Y; Du J; Li A; Zhu Y; Xu L; Sun K; Ma S; Guo T;
    Alzheimers Res Ther; 2023 Feb; 15(1):30. PubMed ID: 36750884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apolipoprotein E epsilon4 allele is unrelated to cognitive or functional decline in Alzheimer's disease: retrospective and prospective analysis.
    Kleiman T; Zdanys K; Black B; Rightmer T; Grey M; Garman K; Macavoy M; Gelernter J; van Dyck C
    Dement Geriatr Cogn Disord; 2006; 22(1):73-82. PubMed ID: 16699282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction between vascular factors and the APOE ε4 allele in predicting rate of progression in Alzheimer's disease.
    Mielke MM; Leoutsakos JM; Tschanz JT; Green RC; Tripodis Y; Corcoran CD; Norton MC; Lyketsos CG
    J Alzheimers Dis; 2011; 26(1):127-34. PubMed ID: 21593560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockers and cognitive decline in Alzheimer's disease: the importance of blood-brain barrier penetration and APOE ε4 carrier status.
    Ouk M; Wu CY; Rabin JS; Jackson A; Edwards JD; Ramirez J; Masellis M; Swartz RH; Herrmann N; Lanctôt KL; Black SE; Swardfager W
    Alzheimers Res Ther; 2021 Feb; 13(1):43. PubMed ID: 33573702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.